Clinical trials: Proof of Concept
Sickle Cell Disease
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
- Trial name
- NCT04055818
- Testing
- Nicotinamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- EpiDestiny, Inc.
Schizophrenia
Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters.
- Trial name
- NCT05563818
- Testing
- WinterLight Mobile Phone Speech Analysis
- Where
- 4 sites in Algeria, Egypt and 2 more
- Volunteers
- 57 people
- Sponsor
- Hikma Pharmaceuticals LLC
Paroxysmal Nocturnal Hemoglobinuria
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of OMS906 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients who have a…
- Trial name
- NCT05972967
- Testing
- OMS906
- Where
- 5 sites in Germany, Greece and 2 more
- Volunteers
- 12 people
- Sponsor
- Omeros Corporation
Knee Cartilage Lesion
Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation
The purpose of this study was to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a single intra-articular (i.a.) administration of LNA043 in regenerating the articular cartilage of the knee, in a…
- Trial name
- ACI (NCT03334812)
- Testing
- LNA043
- Where
- 2 sites in Austria
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Scar Pain
Dysport in Post-Surgical Neuralgia
The study is designed to determine whether a currently licensed version of botulinum toxin (Dysport®) is effective for the treatment of pain that has developed and/or persisted for months or years around the scar of a previous…
- Trial name
- PMOD03 (NCT03663101)
- Testing
- Lidocaine, Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Ipsen
Migraine Headache
A Study in Migraine Prevention
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
- Trial name
- NCT01184508
- Testing
- LY2300559
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Malaria, Malaria Vaccines
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
GSK Biologicals in partnership with the Malaria Vaccine Initiative at PATH is developing a candidate malaria vaccine GSK 257049 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00289185
- Testing
- RTS,S/AS02D, Engerix-B®, TETRActHib™
- Where
- Tanzania
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dermatomyositis
Study of NM8074 in Patients with Dermatomyositis (DM)
This is a Phase II, open-label, multicenter study to evaluate the safety and efficacy of NM8074 administered via intravenous infusion in patients with Dermatomyositis (DM).
- Trial name
- NCT06887738
- Testing
- NM8074
- Volunteers
- 8 people
- Sponsor
- NovelMed Therapeutics
Presbyopia
Multifocal High ADD Contact Lens Proof of Concept Trial
The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.
- Trial name
- NCT02117544
- Testing
- Lotrafilcon B multifocal contact lenses (new), Lotrafilcon B multifocal contact lenses
- Volunteers
- 268 people
- Sponsor
- Alcon Research
Androgenetic Alopecia
Activated PRP for Treatment of Androgenetic Alopecia
A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA.
- Trial name
- NCT05348343
- Testing
- Autologous platelet-rich plasma
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Santiste Medical Inc.
Celiac Disease, Non-celiac Gluten Sensitivity
Probiotic BL NCC 2705 and Gluten Sensitivity
The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.
- Trial name
- NCT03775499
- Testing
- Intervention 1 : BL NCC 2705 + Maltodextrin, Intervention 1 : Maltodextrin, Intervention 2 : BL NCC 2705 + Maltodextrin
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Société des Produits Nestlé (SPN)
Hypertension
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
- Trial name
- NCT01373086
- Testing
- LFF269, Eplerenone
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Relapsing-Remitting Multiple Sclerosis
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
The primary objective of the study was to measure the change in bladder function as measured by Urogenital Distress Inventory (UDI)-6 compared to baseline over 6 months of Tysabri treatment.
- Trial name
- TRUST (NCT00818038)
- Testing
- BG0002 (natalizumab)
- Volunteers
- 30 people
- Sponsor
- Biogen
Parkinson's Disease
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
The primary objective of the study is to assess the efficacy, carbidopa dose response and safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment of Parkinson's disease (PD) patients with…
- Trial name
- PARPOC (NCT01766258)
- Testing
- ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo
- Volunteers
- 117 people
- Sponsor
- Orion Corporation, Orion Pharma
PTSD
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD).
- Trial name
- NCT01339689
- Testing
- Ganaxolone
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Marinus Pharmaceuticals
SARS CoV 2 Infection
The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 (Coronavirus Disease-19) Infection in Healthy Volunteer Individuals
This is a proof-of-concept double-blind cluster randomized (1:1) parallel study. The randomization unit is healthy volunteers who have no symptoms of COVID-19 at the start of the study and have not been infected with the…
- Trial name
- NCT05552950
- Testing
- BioBlock® antiviral nasal spray
- Where
- Estonia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chemi-Pharm AS
Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
- Trial name
- KEYNOTE144 (NCT02362048)
- Testing
- ACP-196, ACP-196 in combination with pembrolizumab
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Acerta Pharma BV
Parkinson's Disease
Deep Brain Stimulation Effects Study
The purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person.
- Trial name
- NCT01098565
- Testing
- Study device HFR0001
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- MedtronicNeuro
Ovarian Hyperstimulation Syndrome
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
- Trial name
- NCT00329693
- Testing
- Norprolac
- Where
- 7 sites in Spain
- Volunteers
- 182 people
- Sponsor
- Ferring Pharmaceuticals